Алкогольная болезнь печени: новое в американском и европейском подходах

1. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic Liver Disease. Am J Gastroenterol 2010; 105: 14–32.
2. Mathurin P, Hadengue A, Bataller R et al. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399–420.
3. Blachier M, Leleu H, Peck-Radosavljevic M. et al. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 2013; 58: 593–608.
4. Chalasani N, Younossi Z, Lavine JE et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811–26.
5. Пиманов С.И. Алкогольная болезнь печени: фокус на лечение гепатита. Cons. Med. Гастроэнтерология (Прил.). 2012; 1: 80–5.
6. Gramenzi A, Caputo F, Biselli M et al. Review article: alcoholic liver disease – pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006; 24 (8): 1151–61.
7. Singer M, Feick P, Gerloff A. Alcohol and smoking. In.: Environment and lifestyle – effects on disorders of the digestive tract. Ed. H.E.Blum, R.H.Hunt. J Scholmerich Karger 2011: 177–83.
8. Seth D, Haber P, Wing-Kin Syn et al. Pathogenesis of alcohol-induced liver disease. J Gastroenterol Hepatol 2011; 26: 1089–105.
9. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38: 613–19.
10. Cantoni GL. The Nature of the Active Methyl Donor Formed Enzymatically from L-Methionine and Adenosinetriphosphate. J Am Chem Soc 1952; 74 (11): 2942–3.
11. Подымова С.Д. Адеметионин: фармакологические эффекты и клиническое применение препарата. РМЖ. 2010; 18 (13): 800–6.
12. Mato JM, Martínez-Chantar ML, Lu SC. Methionine Metabolism and Liver Disease. Annu Rev Nutr 2008; 28: 273–93.
13. Шульпекова Ю.О. Таргетная терапия заболеваний печени. Справ. поликлин. врача. 2009; 5: 21–5.
14. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012; 92 (4): 1515–42.
15. McClain CJ, Hill DB, Song Z. S-adenosylmethionine, cytokines, and alcoholic liver disease. Alcho. 2002; 27 (3): 185–92.
16. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews. 2006; Issue 2, Art. No.: CD002235.
17. Frezza M. A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis. Ann Ital Med Int 1993; 8 (Suppl.): 48S–51S.
18. Zhu SS, Dong Y, Gan Y et al. Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children [Article in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010; 24 (2): 136–8.
19. Hardy M, Coulter I, Morton SC et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/Technology Assessment Number 64 (Prepared by Southern California Evidence-based Practice Center under Contract No. 290-97-0001). AHRQ Publication No. 02-E034. Rockville, MD: Agency for Healthcare Research and Quality. October 2002.
20. Purohit V, Abdelmalek M, Barve S et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007; 86: 14–24.
21. Medici V, Virata MK, Peerson J et al. S-adenosyl-L-methionine treatment of alcoholic liver disease: а double-blind, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35 (11): 1960–5.
22. Mato JM, Camara J, Fernandez de Paz J et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30 (6): 1081–9.

С.И.Пиманов, Е.В.Макаренко, Л.В.Тихонова

Витебский государственный медицинский университет, Беларусь